Piper Sandler Maintains Overweight on Sarepta Therapeutics, Maintains $157 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Biren Amin maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $157 price target.
June 21, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Biren Amin maintains an Overweight rating on Sarepta Therapeutics with a $157 price target, indicating continued confidence in the company's stock performance.
The maintained Overweight rating and price target of $157 by Piper Sandler suggests strong confidence in Sarepta Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100